AstraZeneca plc vs Bath & Body Works Inc — how do they compare? AstraZeneca plc trades at $158.15 (market cap $248.14B), while Bath & Body Works Inc trades at $18.9 (market cap $3.81B). The key difference: AstraZeneca plc is far larger — about 65.1× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays the higher dividend (4.24%). Which is the better fit depends on your goals.
| AZN | BBWI | |
|---|---|---|
Market Cap | $248.14B | $3.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $31.87 |
52-Week Low | $147.06 | $14.85 |
Enterprise Value | $275.41B | $7.70B |
Dividend Yield | 2.01% | 4.24% |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →